Associate Professor Federico Fenaroli has reached a significant milestone in his career with the awarding of a major research project from the Norwegian Research Council (NFR).
The project, titled “Development of Targeted Lipid Nanoparticles Enclosing miRNA for the Treatment of HER2-Positive Breast Cancer (MICROTARGET),” has secured close to 12.5 million NOK in funding.
This is Federico’s first large-scale project as the principal investigator. He will lead a team that includes three positions, two full-time and one part-time, in addition to taking on the role of project manager himself. The project aims to develop new treatments for HER2-positive breast cancer using nanoparticles that carry miRNA, which could potentially improve treatment outcomes for patients with this aggressive cancer type.
Federico expressed great gratitude for the opportunity and is looking forward to advancing research that could have a significant impact on cancer treatment.
“This project gives us the opportunity to contribute to a field of great medical importance. We hope our research can lead to new and more effective treatment methods for HER2-positive breast cancer,” Federico Fenaroli says.
The project will span several years and involve collaboration with international partners, as well as the use of advanced technology in lipid nanoparticles and molecular biology. This marks an important step for UiS in biomedical research, and we look forward to following the development of the project.